Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up

Company Galapagos NV Nasdaq

Equities

GLPG

US36315X1019

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
28.63 USD -0.49% Intraday chart for Galapagos NV -0.97% -29.57%
Apr. 08 Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024 CI
Mar. 28 Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT

Business Summary

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Number of employees: 1,123

Sales per Business

EUR in Million2022Weight2023Weight Delta
Medicines
100.0 %
505 100.0 % 240 100.0 % -52.56%

Sales per region

EUR in Million2022Weight2023Weight Delta
United States
100.0 %
414 82.0 % 240 100.0 % -42.12%
Europe
0.0 %
91 18.0 % 0 0.0 % -99.98%

Managers

Managers TitleAgeSince
Paulus Stoffels CEO
 Chief Executive Officer 62 22-03-31
Thad Huston DFI
 Director of Finance/CFO 54 23-05-31
Sandra Cauwenberghs IRC
 Investor Relations Contact - 20-10-31
Valeria Cnossen LAW
 General Counsel 51 22-07-31
Annelies Missotten HRO
 Human Resources Officer 52 18-01-31
Annelies Denecker SEC
 Corporate Secretary - -
Phil Dudfield PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Andrew Dickinson BRD
 Director/Board Member 54 Mar. 26
Jérôme Contamine BRD
 Director/Board Member 66 22-04-25
Simon Sturge BRD
 Director/Board Member 65 23-09-18
Linda Higgins BRD
 Director/Board Member 62 19-10-21
Paulus Stoffels CEO
 Chief Executive Officer 62 22-03-31
Susanne Antonie Schaffert BRD
 Director/Board Member 57 23-06-11
Peter Guenter BRD
 Director/Board Member 61 19-04-29
Lena Elisabeth Svanberg BRD
 Director/Board Member 63 20-04-27
Dan Baker BRD
 Director/Board Member 74 22-04-25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 65,897,071 49,184,974 ( 74.64 %) 0 74.64 %

Shareholders

NameEquities%Valuation
GILEAD SCIENCES, INC.
25.35 %
16,707,477 25.35 % 534 M $
Van Herk Investments BV
7.035 %
4,635,672 7.035 % 148 M $
CAPFI DELEN Asset Management NV
0.2706 %
178,305 0.2706 % 6 M $
De Grote Voskuil Capital BV
0.2352 %
155,000 0.2352 % 5 M $
FundQuest Advisor
0.2230 %
146,941 0.2230 % 5 M $
Goldman Sachs Advisors BV
0.2170 %
143,000 0.2170 % 5 M $
Econopolis Wealth Management NV
0.1214 %
80,000 0.1214 % 3 M $
Allianz Global Investors GmbH (Netherlands)
0.1124 %
74,100 0.1124 % 2 M $
Dimensional Fund Advisors Ltd.
0.1120 %
73,836 0.1120 % 2 M $
OP Asset Management Ltd.
0.0986 %
65,000 0.0986 % 2 M $
NameEquities%Valuation
EcoR1 Capital, LLC
9.873 %
6,505,890 9.873 % 209 M $
EcoR1 Capital, LLC
8.735 %
5,756,268 8.735 % 185 M $
Fidelity Management & Research Co. LLC
6.425 %
4,233,803 6.425 % 136 M $
BVF, Inc.
2.906 %
1,915,109 2.906 % 62 M $
Segall Bryant & Hamill LLC
1.327 %
874,728 1.327 % 28 M $
Prosight Management LP
1.255 %
827,294 1.255 % 27 M $
PRIMECAP Management Co.
1.030 %
678,877 1.030 % 22 M $
Deerfield Management Co. LP (Private Equity)
0.9441 %
622,112 0.9441 % 20 M $
Wellington Management Co. LLP
0.7515 %
495,217 0.7515 % 16 M $
Finepoint Capital LP
0.6960 %
458,659 0.6960 % 15 M $

Company contact information

Galapagos NV

Industriepark Mechelen Noord Generaal de Wittelaan L11 A3

2800, Mechelen

+32 1 534 29 00

http://www.glpg.com
address Galapagos NV(GLPG)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Galapagos NV

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
27.12 EUR
Average target price
38.43 EUR
Spread / Average Target
+41.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. GLPG Stock
  5. Company Galapagos NV